Biomarkers in colorectal cancer

Author(s):
Swets, M.
Published
2020
Publication type
Doctoral Thesis

Abstract

Potential relevant biomarkers can be found at different levels in tumour development

and disease progression. This thesis is divided into three overarching parts. Colorectal

cancer was studied from a population-based perspective (part I) to a molecular level,

detailed as protein expression (part II) and (epi)genetics (part III), as indicated in Figure 2. In part I the use of adjuvant chemotherapy in patients with locally advanced rectal cancer, who underwent resection after preoperative (chemo)radiotherapy, was evaluated in a meta-analysis based on individual patient data. Since four randomized controlled trials individually did not end the ongoing debate about the role of adjuvant chemotherapy 14,68-70. In part II the ability by tumour cells to evade the immune recognition was studied, especially the role of the non-classical HLA class I molecule HLA-G was studied in detail. In part III, an epigenetic biomarker, LINE-1 methylation level, was studied in a dedicated stage II colon cohort. In addition, an established genetic biomarker for colon cancer, MSI, was studied in a large rectal cancer cohort.

Colorectal cancerBiomarkersAdjuvant chemotherapyHLA-GMSILINE-1
Defense date
2020-01-07
Language
English
Supervisor(s)
Velde, C.J.H. van de; Gelderblom, A.J.
Advisor(s)
Kuppen, P.J.K.
Committee member(s)
Putter, H.; Morreau, J.; Rutten, H.J.T.; Laarhoven, H.W.M. van
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden
hdl
1887/82484
ISBN(s)
9789463239509